There are 3158 resources available
Role of Long-term Efficacy, Safety Outcomes and Different Routes of Administration in the Advance Disease Setting: the RCC Experience
Presenter: Laurence Albiges
Session: Bristol Myers Squibb - Developments in Genitourinary Cancer Management: Joint Decision Making in MIUC and Advanced RCC
Resources:
Webcast
Optimising 1L treatment in clinical practice
Presenter: Tony S.K. Mok
Session: Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy
Resources:
Webcast
Added value of Liquid Biopsy testing in advanced cancer – IMPRESS NORWAY
Presenter: Åslaug Helland
Session: Illumina - Liquid biopsy-based biomarkers for cancer profiling and monitoring: current and future applications
Resources:
Webcast
Improving Joint Decision Making in Genitourinary Cancers
Presenter: Michael Jewett
Session: Bristol Myers Squibb - Developments in Genitourinary Cancer Management: Joint Decision Making in MIUC and Advanced RCC
Resources:
Webcast
Practical strategies for managing adverse events
Presenter: Enriqueta Felip
Session: Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy
Resources:
Webcast
The Value of Liquid Biopsy Testing in Colorectal Cancer: The Patient Advocacy Perspective
Presenter: Stephen Rowley
Session: Illumina - Liquid biopsy-based biomarkers for cancer profiling and monitoring: current and future applications
Resources:
Webcast
ALK+ aNSCLC treatment expectations now and in the future
Presenter: Tony S.K. Mok
Session: Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy
Resources:
Webcast
Panel discuss
Presenter: Umberto Malapelle, Magdalena Meissner, Åslaug Helland, Stephen Rowley
Session: Illumina - Liquid biopsy-based biomarkers for cancer profiling and monitoring: current and future applications
Resources:
Webcast
Closing Remarks
Presenter: Laurence Albiges
Session: Bristol Myers Squibb - Developments in Genitourinary Cancer Management: Joint Decision Making in MIUC and Advanced RCC
Resources:
Webcast
Meeting close
Presenter: Tony S.K. Mok
Session: Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy
Resources:
Webcast